Tech con­glom­er­ate buys Me­di­da­ta for $5.7B; Alexan­dria teams up with Co­lum­bia for sec­ond Launch­Labs; So­bi all in on ema­palum­ab

→ Clin­i­cal tri­al soft­ware provider Me­di­da­ta is get­ting ac­quired in a $5.8 bil­lion deal. The all-cash buy­er, Das­sault Sys­temes, is a French tech­nol­o­gy com­pa­ny that’s his­tor­i­cal­ly fo­cused on 3D de­sign and en­gi­neer­ing. “Life sci­ence is go­ing to go through an ac­cel­er­at­ed dig­i­ti­za­tion of its own process­es, ba­si­cal­ly,” Das­sault CEO Bernard Charles told CN­BC. Hav­ing pow­ered op­er­a­tions and da­ta analy­sis for hun­dreds of bio­phar­ma com­pa­nies, CROs and re­searcher cen­ters, Me­di­da­ta’s plat­form is poised to lead the vir­tu­al trans­for­ma­tion in the in­dus­try, he added.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER